Custom Bonding and Chromatography Resins for Small and Large Molecule Purification

Custom Bonding and Chromatography Resins for Small and Large Molecule Purification
Product Description

A wide range of DAVISIL® silica gel grades are available from one kg to multi-ton quantities to meet your application, performance, and economic requirements. DAVISIL® silicas are used to purify nutraceuticals, antibiotics, vaccine adjuvants, oil-based APIs, organic synthesis products (including intermediates and high-value APIs), and biologics. Compared to other competitor silica gel products, DAVISIL® silicas are available in various pore sizes with higher surface area, lower bulk density, and tighter particle size distribution.

Produced by a unique process based on purified organosilicate starting materials, VYDAC® spheroidal silicas are well-defined, highly pure, totally porous separation resins for preparative and process scale users. Developed and utilized in applications for protein, peptide, and oligonucleotide separations, VYDAC® resins provide excellent selectivity, reproducibility, and recovery.

Grace is a pioneer in silica and functionalization technologies, and its scientists continue to develop new and customized solutions beyond our standard range of products, often in close collaboration with customers. Grace’s particle engineering capabilities allow surface, pore, and particle properties to be tuned to meet a customer’s specific requirements. Furthermore, Grace can develop functionalized resins for specific chromatographic applications, including the separation of challenging isomers. Functionalization options include affinity, ion exchange, and reversed / normal phase chemistries. Companies in the nutraceutical and highly regulated pharmaceutical industries have come to depend on the superb quality and performance attributes of Grace silicas.

W. R. Grace & Co

  • US
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator

W. R. Grace & Co

  • US
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator

More Products from W. R. Grace & Co (4)

  • Custom Fine Chemical Manufacturing

    Product Custom Fine Chemical Manufacturing

    Our comprehensive portfolio of services, integrated manufacturing, and regulatory leadership differentiates us as a leading contract development and manufacturing partner. With a proven ability to deliver solutions to complex challenges, Grace’s FCMS supports the entire small molecule development cycle from t...
  • Purification and Formulation of Oily APIs and Omega-3s

    Product Purification and Formulation of Oily APIs and Omega-3s

    Grace resins and excipients improve purity and create better targeted and higher value formulations with enhanced bioavailability. Grace is solving purification and formulation issues in oily APIs and Omega-3s in high quality separation capabilities, customization, reliability and speed to market, and com...
  • Purification and Formulation of Cannabinoids (CBD)

    Product Purification and Formulation of Cannabinoids (CBD)

    Grace has developed and introduced a patented silica based carrier, SYLOID® XDP silica, to directly convert liquid ingredients such as CBD into solid dosage forms. Extracting and purifying CBD from the hemp plant is a multi-step process which focuses on removal of several undesirable impurities. Grace has...
  • Drug Delivery for Enhanced Bioavailability of BCS2 (Poorly Soluble) Compounds

    Product Drug Delivery for Enhanced Bioavailability of BCS2 (Poorly Soluble) Compounds

    Engineered to bring together advanced silica technologies with challenging active pharmaceutical ingredients (APIs) to effectively formulate a large class of poorly soluble but otherwise promising compounds, Grace’s SILSOL® silica-based drug delivery technology provides solutions for poorly soluble active...

W. R. Grace & Co resources (3)

  • News Grace Completes Acquisition of Fine Chemistry Business

    June 01, 2021: W. R. Grace & Co. announced the completion of its acquisition of the Fine Chemistry Services business (“FCS”) of Albemarle Corporation (NYSE: ALB) for approximately $570 million, including $300 million paid in cash and $270 million funded through the issuance to Albemarle of non-participating preferred equity of a newly created Grace subsidiary.
  • Brochure Grace Pharmaceutical Solutions Brochure

    Learn more about Grace's unmatched quality and reproducibility of our fine chemicals, chromatography resins, formulation excipients, and active ingredient delivery technologies.
  • Video Natural Extracts: Unlocking the Potential of Cannabinoid Derived Drugs

    Originally aired during the CPHI Festival of Pharma 2020, this webinar examines the current landscape for cannabinoid derived drugs, including looking at pipeline and approvals, development challenges and regulatory hurdles.